UNMC provides the best, state-of-the-art, advanced patient care, training, education and research programs within USA and in the global healthcare arena.

UNMC has established Centers of Excellence in Cancer Care, Transplantation, Cardiovascular, Neurosciences, Genetics and Biomedical Technology.

UNMC was established in 1881 - Over 125 years of patient care and educational experience.

Over 8,500 professionals work at UNMC to serve every need of a patient with professionalism and compassion. Our staff includes over 1,000 physicians and specialists, 1,500 nurses and over 6,000 other support staff ready to serve all patient needs.

UNMC operates one of the foremost healthcare facilities for Cancer Care, Solid Organ and Stem Cell Transplantation, Urology, Epilepsy, Minimally-Invasive Robotic Surgeries and other treatment options in the USA; it has extensive experience and success in the planning and execution of specialty healthcare and patient care services.

UNMC is located on 112 acres (over 45 hectors) with 29 major healthcare and administration facilities.

UNMC has 639 licensed beds.

• US News & World Report rated UNMC as one of the “Best Hospitals” for Cancer Care and Rheumatology in the USA. It also rated UNMC for its Best Technology Recognition – giving it a 100% grade its medical technology advancements.

• UNMC is the only Center in the United States with two physicians on the National Comprehensive Cancer Network’s (NCCN) board of directors and the only National Cancer Center (NCI) designated cancer center in this region of the country.

•  UNMC’s Eppley Center is one of the only 20 NCCN (National    Comprehensive Cancer Network) designated distinguished centers in USA.

• UNMC’s team leads the World Health Organization’s New Lymphoma Classification Group.

• UNMC is one of the three busiest transplant centers in the USA. Over 10,500 transplants completed, with over 3,600 bone marrow/stem cell transplants.

• UNMC is ranked among the top 10 “Best Places to work for Postdocs” by the Scientist Magazine.

   

   

   

   

   

   

   

  Bone Marrow and Stem Cell Transplantation

   

• UNMC’s research led to the first peripheral stem cell transplant by Dr. Anne Kessinger in 1983, now a standard therapy around the world.

• UNMC performed the first bone marrow transplant in Nebraska.

• UNMC physicians performed the first umbilical cord blood transplant in an Omaha hospital (1993).

• UNMC physicians performed the first outpatient bone marrow transplant (1993).

• UNMC has been performing kidney transplants for 33 years.

• UNMC is one of only four USA’s Health & Human Service Department’s recognized Intestinal Transplant Centers in the USA.

• UNMC was the first healthcare institution to create Combined Liver/Small Bowel Transplant Program.

• UNMC Surgeons performed the first two successful small bowel/liver transplants (1991).

• UNMC is one of the five most active Pancreas and Kidney/Pancreas Transplantation programs in USA.

• NMC is a leader in living-related kidney & liver transplantation.

• UNMC/Clarkson Hospital began pancreas-only transplants (1991).

• UNMC developed the external liver bypass unit (1991).

• UNMC began the islet transplantation program for Type I (insulin dependent) diabetics (1992).

• UNMC surgeons performed the first Nebraska liver transplant using organs from living, related donors (1993).

• UNMC physicians performed the first islet cell transplant in Nebraska (1994).

• UNMC surgeons performed the first lung transplant (1996).

• UNMC surgeons performed the world's first removal of two cancerous kidneys simultaneously through use of a laparoscope (1997).

• A team of UNMC healthcare specialists performed the first-ever infusion of billions of donor liver cells to correct a life-threatening liver deficiency that would otherwise require a liver transplant (1997).

• UNMC surgeons are the first in Nebraska to implant a biventricular assist device to keep patient alive until a donor heart can be located.

• UNMC researcher, Dr. Denman Herman, first proposed the theory of antioxidants and their effects on the aging process (1950).

• UNMC researcher developed the skin test for Marfan's Syndrome.

• UNMC was the first to treat a patient in the U.S. with antisense therapy for leukemia.

• UNMC ophthalmologist, Dr. Carl Camras, discovered a new glaucoma drug, Itanoprost (1996). This drug is today the most widely used glaucoma drug in the world.

• UNMC physicians discovered the three-drug combination therapy that works best in treating rheumatoid arthritis.

• A team of UNMC surgeons performed the first baroscopic repair of an aortic aneurysm.

• UNMC researchers were major contributors (along with researchers from five other institutions)  in the findings which showed that diffused large B-cell lymphoma, the most common form of non-Hodgkin's lymphoma, is actually two distinct diseases.

• UNMC researchers helped make the diagnostic breakthrough with Burkett’s lymphoma. Difficulties in the distinction between Burkett’s lymphoma and diffused large-B-cell lymphoma may be resolved by the use of gene-expression patterns. This study is detailed in The New England Journal of Medicine (June 2006).

• UNMC researcher developed the world's first genetically engineered mouse model to explain how folic acid protects against birth defects such as neural tube defects and cleft lip and palate (1999).

• The first robotic surgery was performed on a human in Nebraska for an inflamed bowel (2000).

• UNMC researchers were in first in the US to begin study on safety, effectiveness of potential treatment of acute myeloid leukemia (AML).

• Two proteins that play a key role in aneurysms were identified by UNMC researchers.

• UNMC surgical team was the first in the world to use robotic system for complex urinary diversion.

• UNMC scientists identified a piece of Coxsackie virus B that controls its ability to grow in heart cells; this identification may lead to better treatments or vaccines for myocarditis.

• UNMC scientists developed a new technology to prevent rejection of porcine organs without severe immune suppression.

• Scientists at UNMC and Columbia University Medical Center discovered a new vaccine approach that successfully prevents the death of brain cells in a mouse model of Parkinson’s disease.

• Hematological Malignancies program, led by Dr. Julie Vose, Chair of the Oncology/Hematology Section and Dr. John Chen, are developing new tools for diagnosis and new therapies for blood cancers. More specifically, UNMC researchers are working on tumor vaccines as well as drug discovery and delivery programs.

• UNMC’s Breast Cancer Program, led by Dr. James Shull has identified genetic regions associated with an increased risk of estrogen-induced breast cancers.  Breast cancer vaccine clinical trials are also currently worked on at UNMC.

• UNMC is the only site currently offering a clinical study of an anti-tumor vaccine for patients with prostrate cancer that cannot be managed with current therapies. Dr. Ralph Hauke is currently studying the benefits of a new vaccine given to patients with prostate cancer, which is intended to boost the patient’s immune system and to reduce the risk of relapse.

• UNMC is also active in the development of nanotechnology used in implementing effective and improved methods for the diagnosis and treatment of cancer. The field of nanotechnology uses tiny particles which are one ten-millionth the size of the human body and much smaller than living cells. With its tiny sized non-particles, researchers are able to spot and to attack cancers more precisely and ultimately lead to providing core effective drug delivery in treating cancers.

• Over 40 Scholarships to participants from over a dozen countries for Clinical Excellence and No-Cost training programs in bone marrow and stem cell transplantations were provided during 2001-2005.